Use of L-PRF in the treatment of osteoradionecrosis

Authors

DOI:

https://doi.org/10.33448/rsd-v11i5.28140

Keywords:

L-PRF; Bone necrosis; Bisphosphonate.

Abstract

Osteonecrosis is a pathology caused by necrosis of the gnathic bones of the maxilla and mandible. Either through antiresorptive drugs or radiotherapy. L-PRF is a platelet concentrate composed of leukocytes and growth factors capable of restoring vascularization and healing of soft and hard tissues. In addition to being the newest alternative treatment for osteonecrosis. In view of this, the work aims to evaluate the effectiveness of L-PRF in the prevention and treatment of osteonecrosis, and to clarify the mechanisms of this platelet concentrate in maxillary and mandibular osteonecrosis, in addition to other therapeutic approaches combined with L-PRF. Regarding the methodology, it is based on a literature review with a qualitative approach, which used the PUBMED, Google Scholar, Medline and IBECS databases. In the initial research, it resulted in 377 articles, after applying the filters that refer to articles published between 2017 and 2022, it generated a total of 21 articles chosen. According to the literature, L-PRF is effective in osteonecrosis, however, there are differences in the literature, as well as the fact that there is still no gold standard treatment. Therefore, L-PRF is effective, but it is not yet standardized, while each case of osteonecrosis has its peculiarity. However, when combined with other forms of treatments such as human bone morphogenetic protein (PMBs), the synergistic effect of these therapeutics accelerates the patient's healing process.

References

Asaka, T., Ohga, N., Yamazaki, Y., Sato, J., Satoh, C., & Kitagawa, Y. (2017). Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clinical Oral Inventigations, 21, 2165–2172. 10.1007/s00784-016-2004-z.

Batalhas, J.L., Jaramillo, P.U., & Onofre, A.O. (2018). Caso Clínico: Aplicación de Fibrina Rica en Factores de Crecimiento en el Tratamiento de Osteonecrosis de los Maxilares por Bisfosfonatos. OdontoInvestigación, 4(2). https://doi.org/10.18272/oi.v4i2.1279.

Bouland, C., Meuleman, N., Widelec, J., Keiani-Mothlagh, K., Voisin, C., Lagneaux, L., & Philippart, P. (2021). Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF. Journal of Stomatology, Oral and Maxillofacial Surgery, 122(2), 212-218. https://doi.org/10.1016/j.jormas.2020.05.024.

Cano-Durán, J. A., Peña-Cardelles, J., Ortega-Concepción, D., Paredes Rodríguez, V.M., García-Riart, M., & López-Quiles, J. (2017). The role of Leukocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent, 9(8), e1051-9. doi:10.4317/jced.54154.

Cortese, A., Casarella, A., Howard, C. M., & Claudio, P. P. (2021). Epi-Mucosa Fixation and Autologous Platelet-Rich Fibrin Treatment in Medication-Related Osteonecrosis of the Jaw. Dentistry Journal, 9(5), 50. https://doi.org/10.3390/dj9050050.

Coterón, M.G. (2019). Empleo de concentrados plaquetarios autólogos en el tratamiento y la prevención de la osteonecrosis de los maxilares inducida por medicamentos. Hacia una revisión sistemática / Autologous platelet concentrates for medication related osteonecrosis of the jaw treatment and prevention. A systematic review approach. Cient. Dent. 16(3), 181-190.

Elvira, R. F., Cano- Durán, J. A., Concepción, D. O., & Cardelles, J. F. P. (2018). New Alternatives on the Treatment of Bisphosphonates Related Osteonecrosis of the Jaws: A Review and Case Study/ Revisión de Literatura sobre Nuevas Alternativas en el Tratamiento de la Osteonecrosis Maxilar por Bisfosfonatos: Estudio de un Caso. Psychologia Latina, volume especial, 131-133.

Giudice, A., Barone, S., & Bennardo, F. (2020). Effect of Platelet-Rich Fibrin in Surgical Treatment of Medication-Related Osteonecrosis of the Jaw. Journal of Oral and Maxillofacial Surgery, 78(10), 1659. https://doi.org/10.1016/j.joms.2020.05.051.

Giudice, A., Antonelli, A., Muraca, D., & Fortunato, L. (2020). Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report. Indian Journal of Dental Research, 31(5), 813-818. 10.4103/ijdr.IJDR_689_19.

Gönen, Z. B., & Asan, C., Y. (2017). Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin. The Journal of Craniomandibular & Sleep Practice, 35(5), 332-336. https://doi.org/10.1080/08869634.2016.1203093.

Maluf, G., Caldas, R. J., & Santos, P. S. S. (2017). Use of Leukocyte- and Platelet-Rich Fibrin in the Treatment of Medication-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery, 76(1), 88-96. https://doi.org/10.1016/j.joms.2017.06.004.

Mourão, C. F.A.B., Calasans-Maia, M. D., Fabbro, M. D., Vieira, F. L. D., Machado, R. C. M., Miron, R. J., & Alves, G. G. (2020). The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series. Journal of Stomatology, Oral and Maxillofacial Surgery, 121(1), 84-89. https://doi.org/10.1016/j.jormas.2019.02.011.

Parise, G. K., Quadros, M. V. H., Pereira, E. M., Costa, B. N., Patussi, C., Schussel, J. L., & Sassi, L. M. (2021). The role of fibrin rich platelets and leukocytes (L-PRF) in the medication-related osteonecrosis of the jaw: report of premaxilla necrosis. Journal of Oral Diagnosis, 6, e2021-0012. 10.5935/2525-5711.20210012.

Park, J.H., Kim, J.H., & Kim, S.J.(2016). Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?. Journal of Oral and Maxillofacial Surgery, 76(6), 1176-1184. https://doi.org/10.1016/j.joms.2016.12.005.

Şahin, O., Aliyev, T., & Tatar, B. (2018). Leucocyte-Rich and Platelet-Rich Fibrin (L-PRF) for the Treatment of Medication- Related Osteonecrosis of the Jaw(MRONJ) with Long Term Follow- up. Biomedical Journal of Scientific &Technical Research, 2(2), 2511-2513. 10.26717/BJSTR.2018.02.000729.

Şahin, O., Tatar, B., Ekmekcioğlu, C., Aliyev, T., & Odabaşı, O. (2020). Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience. Journal Of Clinical and Experimental Dentistry, 12(8), e771–e776. 10.4317/jced.56837.

Schliephake, H., Sicilia, A., Nawas, B. A., Nikos, D., Gruber, R., Jepsen, S., Milinkovic, I., Mombelli, A., Navarro, J. M., Quirynen, M., Rocchietta, I., Schiødt, S. S., Stähli, A., Stavropoulos, A., & Suárez, L. M. S. (2018). Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018. Clinical Oral Implants Research, 29(Suppl.18), 93-99. 10.1111/clr.13270.

Steller, D., Herbst, N., Pries, R., Juhl, D., & Hakim, S. (2018). Positive impact of Platelet-rich plasma and Platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid. Scientific Reports, 9, 8310. https://doi.org/10.1038/s41598-019-43798-z.

Szentpeteri, S., Schimidt, L., Restar, L., Csaki, & G., Szabo, G. (2020). The Effect of Platelet-Rich Fibrin Membrane in Surgical Therapy of Medication-Related Osteonecrosis of the Jaw. Journal of Oral and Maxillofacial Surgery, 78(5), 738-748. https://doi.org/10.1016/j.joms.2019.12.008.

Tenore, G., Zimbalatti, A., Rocchetti, F., Graniero, F., Gaglioti, D., Mohsen, A., Caputo, M., Lollobrigida, M., Lamazza, L., Biase, A., Barbarto, E., & Romeo, U. (2020). Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. Journal of Clinical Medicine, 9(11), 3505. https://doi.org/10.3390/jcm9113505.

Viana, M. V. G., Carvalho, M. M. M., Fialho, P. V., Cardoso, L. C., Lasso, D. M. M., Moreira, C. V. A., Seixas, A. M., & Padilha, W. S. M. (2019). Considerações clínicas sobre o uso do L-PRF na terapêutica de osteonecrose medicamentosa dos maxilares: relato de caso / Clinical considerations on the use of do L-PRF in the medicinal therapeutics therapeutics: case report. Brazilian Journal of Health Review, 2(4), 2272. https://doi.org/10.34119/bjhrv2n4-095.

Downloads

Published

04/04/2022

How to Cite

CARVALHO, R. de A. .; GOMES, A. V. S. F.; FERRAZ, R. A. R. .; CASTRO, F. Ângela S. .; PEREIRA, E. M. L.; FERREIRA , G. L. C.; FORTALEZA, V. G. .; FONTENELE, M. Éryka G. de B. Use of L-PRF in the treatment of osteoradionecrosis. Research, Society and Development, [S. l.], v. 11, n. 5, p. e22111528140, 2022. DOI: 10.33448/rsd-v11i5.28140. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/28140. Acesso em: 21 nov. 2024.

Issue

Vol. 11 No. 5

Section

Health Sciences

License

Copyright (c) 2022 Romayla de Andrade Carvalho; Ana Viviam Souza Ferro Gomes; Rodolfo Adriano Rocha Ferraz; Francisca Ângela Sousa Castro; Estefany Monteiro Lopes Pereira; Gerson Luís Castro Ferreira ; Vitória Gindri Fortaleza; Maria Éryka Giovanna de Brito Fontenele

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.